Tacrolimus Dimension Reagent - Registration nº 10345161332 - Class of Risk II 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 Siemens Healthcare Diagnostics Inc. 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    1265
  • 날짜
    2013-08-23
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    Inaccuracy is typically characterized by one or more high TACR results after a period of equipment inactivity. Subsequent results from the same well may show results with decreased values. Falsely decreased or falsely elevated test results may lead to impaired immunosuppressive medication dosage. Increasing the dosage may cause toxicity in the patient's organ. Decreased dosage may lead to organ rejection. If used after long periods of on-board storage (> 2 days) combined with standby periods of the equipment can increase the magnitude of elevation and decrease of results, ie the reduction of on-board stability can result in inaccuracy and in the inaccuracy of quality controls and patient outcomes. Accordingly, imprecision is typically characterized by one or more high TACR results after a period of equipment inactivity. Subsequent results from the same well may show results with decreased values. High discordant results can be raised 2-fold from the expected value and discordant low values ​​can be lowered by fifty percent. The affected lots, that is, the remaining inventory of lots prior to BB4087 must be segregated for collection. As a temporary measure, in order not to interrupt the laboratory routine, lots of reagent cartridge from lot BB4087 will present an "alert card", indicating that the on-board stability is limited to 8 hours. Customers using these batches with the "alert card" should load the Flex reagent cartridges immediately prior to use and remove it after 8 hours. It is also advised not to carry more reagents than the laboratory will use within 8 hours and not pre-hydrate the Tacrolimus Dimension reagents. For further clarification: 0800 129 633. E-mail: subjects. regulatorios.br@siemens.com. Access the warning letter: http://portal.anvisa.gov.br/wps/wcm/connect/ffc77c804ff46d0b8fd3ef6d6e8afaaa/Carta+Portugues+DC+13+08.pdf?MOD=AJPERES
  • 원인
    Results may become inaccurate when the tacrolimus flex reagent is stored on-board in the equipment for 2 days or more. existing and affected lots in brazil: fa3197, fa3267, fb3267, ga3120 - gb3099, gb3176.
  • 조치
    Gathering and destruction. The alert card was adopted as a temporary measure in order not to interrupt the routine of the laboratory while Siemens seeks a definitive solution to this issue.

Manufacturer